Monocyte behaviour and tissue transglutaminase expression during experimental autoimmune encephalomyelitis in transgenic CX3CR1gfp/gfp mice by Navina L. Chrobok et al.
1 3
DOI 10.1007/s00726-016-2359-0
Amino Acids (2017) 49:643–658
ORIGINAL ARTICLE
Monocyte behaviour and tissue transglutaminase expression 
during experimental autoimmune encephalomyelitis in transgenic 
CX3CR1gfp/gfp mice
Navina L. Chrobok1 · Alexandre Jaouen2 · Keith K. Fenrich2,3 · John G. J. M. Bol1 · 
Micha M. M. Wilhelmus1 · Benjamin Drukarch1 · Franck Debarbieux2 · 
Anne‑Marie van Dam1  
Received: 16 June 2016 / Accepted: 1 November 2016 / Published online: 9 November 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
enzyme tissue transglutaminase (TG2), which is present in 
CNS-infiltrated cells in MS patients, is likewise found in 
CX3CR1-GFP+ monocytes in the spinal cord lesions and 
at the luminal side of the vasculature during EAE. It might 
thereby contribute to adhesion and crawling of monocytes, 
facilitating extravasation into the CNS. Thus, we put for-
ward that interference with monocyte adhesion, by e.g. 
inhibition of TG2, should be applied at a very early stage 
of EAE and possibly MS, to effectively combat subsequent 
pathology.
Keywords Cell crawling · Intravital microscopy · 
Immunohistochemistry · Multiple sclerosis
Abbreviations
CFA  Complete Freund’s adjuvant
CNS  Central nervous system
EAE  Experimental autoimmune encephalomyelitis
GFP  Green fluorescent protein
IVM  Intravital microscopy
MOG  Myelin oligodendrocyte glycoprotein
MRI  Magnetic resonance imaging
MS  Multiple sclerosis
TG2  Tissue transglutaminase
Introduction
Multiple sclerosis (MS) is a chronic inflammatory and 
demyelinating disease of the central nervous system (CNS) 
that manifests in a wide range of clinical symptoms includ-
ing sensory, motor and cognitive disabilities (Bobholz and 
Rao 2003; Sospedra and Martin 2005). About 85% of MS 
patients show a relapsing–remitting disease course with 
a pathological inflammatory phenotype characterized by 
Abstract Leukocyte infiltration into the central nervous 
system (CNS) is a key pathological feature in multiple scle-
rosis (MS) and the MS animal model experimental autoim-
mune encephalomyelitis (EAE). Recently, preventing leu-
kocyte influx into the CNS of MS patients is the main target 
of MS therapies and insight into cell behaviour in the circu-
lation is needed for further elucidation of such therapies. In 
this study, we aimed at in vivo visualization of monocytes 
in a time-dependent manner during EAE. Using intravital 
two-photon microscopy (IVM), we imaged CX3CR1gfp/
gfp mice during EAE, visualizing CX3CR1-GFP+ mono-
cytes and their dynamics in the spinal cord vasculature. 
Our observations showed that intraluminal crawling of 
CX3CR1-GFP+ monocytes increased even before the 
clinical onset of EAE due to immunization of the animals. 
Furthermore, intraluminal crawling remained elevated dur-
ing ongoing clinical disease. Besides, the displacement of 
these cells was larger during the peak of EAE compared 
to the control animals. In addition, we showed that the 
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massive influx of leukocytes from the circulation into the 
CNS (Kornek and Lassmann 2003). This cellular influx 
results in the local production of inflammatory mediators, 
activation of resident glial cells, demyelination, oligoden-
drocyte cell death and eventually axonal damage (Kornek 
and Lassmann 2003). So far, preventing the influx of leuko-
cytes is the main target of recently developed MS therapies. 
For instance, the drug natalizumab blocks α4β1-integrin and 
thereby largely prevents interaction of leukocytes with the 
endothelium (Pucci et al. 2011).
Of the infiltrating leukocytes in MS, monocytes were 
shown to be essential for the development of clinical 
symptoms as investigated in experimental autoimmune 
encephalomyelitis (EAE), a well-known animal model 
of MS (Huitinga et al. 1990; Ajami et al. 2011). Infiltra-
tion into the CNS requires an orchestrated collaboration 
of chemokines and adhesion molecules from the inflamed 
endothelium and their receptors on monocytes. Monocytes 
in the bloodstream first roll on the activated and inflamed 
endothelial lumen, before they strengthen their adherence 
and crawl along the lumen to find an extravasation site into 
the inflamed CNS or detach and continue their journey in 
the vasculature (Ley et al. 2007; Man et al. 2007; Gerhardt 
and Ley 2015).
The multifunctional enzyme tissue transglutaminase 
(TG2) has been described to be involved in cell apoptosis 
and monocyte and macrophage adhesion and migration 
in vitro on fibronectin, a constituent of the extracellular 
matrix (ECM) (Akimov and Belkin 2001; Pankov and Yam-
ada 2002). TG2 is upregulated under inflammatory condi-
tions and was shown to be present in monocytes in active 
CNS lesions during MS and EAE (Iismaa et al. 2009; van 
Strien et al. 2015). Monocyte attachment to the endothe-
lium and also differentiation into macrophages lead to a 
boost in TG2 expression (Metha et al. 1987; Eckert et al. 
2014). TG2 present on the surface of monocytes and mac-
rophage can act as a co-receptor for β1- and β3-integrins, 
which are crucial for the adhesion of monocytes (Akimov 
and Belkin 2001; Laudanna et al. 2002). This interaction 
with integrins enhances the affinity of the cells to extracel-
lular matrix proteins, e.g. fibronectin, and therefore pro-
motes monocyte adhesion and migration (Akimov and Bel-
kin 2001). Recent studies from our and other groups have 
shown that knockdown of TG2 or pharmacological inhi-
bition of its activity in rodents suffering from EAE led to 
reduced disease symptoms (Oh et al. 2012; van Strien et al. 
2015). This could, at least partly, be explained by limited 
monocyte migration into the CNS (van Strien et al. 2015), 
but no detailed information about cellular behaviour in vivo 
in this context is known yet.
Nowadays, the presence of demyelinating lesions in MS 
animal models can be visualized in vivo by magnetic reso-
nance imaging (MRI) (Rausch et al. 2003). Furthermore, 
intravenous injection of a contrast-enhancing agent reveals 
blood–brain barrier leakage in MRI, suggesting the pres-
ence of infiltrating cells but not providing information 
about the cell types being present (Rausch et al. 2003). 
Phagocytic cells in the lesions can be identified by MRI 
after injection of ultrasmall superparamagnetic iron oxide 
(USPIO) particles or USPIO-labelled antibodies specific 
for cell surface receptors (Pirko et al. 2003; Rausch et al. 
2003; Floris et al. 2004). Although these techniques are 
non-invasive and provide relevant in vivo information on 
lesion formation, they lack detailed analysis and high reso-
lution of specific cell types present in the spinal cord vascu-
lature before and during clinical symptoms.
As we consider monocytes to be important players dur-
ing the onset and development of clinical symptoms of 
MS and EAE (Kornek and Lassmann 2003), the aim of 
the present study is to investigate the interaction of mono-
cytes with the spinal cord vasculature of EAE mice. For 
this purpose, we used transgenic CX3CR1gfp/gfp mice which 
express green fluorescent protein (GFP) instead of the 
chemokine receptor CX3CR1. This genetic modification 
results in green-labelled monocytes and microglia cells. 
We imaged these CX3CR1-GFP+ cells with intravital two-
photon microscopy (IVM), before and during symptomatic 
disease. Moreover, we analysed the presence of immunore-
active TG2 and caspase-3 in the spinal cord lesions previ-
ously analysed by IVM.
Results
Evaluation of EAE symptoms in CX3CR1gfp/gfp mice 
with a spinal cord window
The window-implanted CX3CR1gfp/gfp mice developed a 
mild EAE disease course when immunized with myeloid 
oligodendrocyte glycoprotein peptide 35–55 (MOG35-55). 
The average maximal clinical score was around 1.5 
(Fig. 1a) and the maximal loss of bodyweight was 8% 
(Fig. 1b). Naive and control animals (immunized with 
complete Freund’s adjuvant, CFA) did not exhibit clini-
cal deficits or loss of body weight at any time during the 
experiment.
IVM of the spinal cord parenchyma of CX3CR1gfp/gfp 
mice
For in vivo imaging, we chose blood vessels draining into 
the central spinal cord vein on both the left and right side 
of the central vein in the region of the vertebrae T13 to L1 
(corresponding to spinal cord levels L4 to S1, Harrison 
et al. 2013). Data from two-photon IVM (Fig. 2) revealed 
two distinct CX3CR1-GFP+ cell localizations in the spinal 
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cord: in the parenchyma (arrowheads) and within the vas-
culature (squares). CX3CR1-GFP+ cells in the spinal cord 
tissue of the naïve animal (Fig. 2a) were microglial-like 
cells with a ramified morphology and thin processes, as 
previously shown (Jung et al. 2000). CFA immunization 
(Fig. 2b) seemed to bring the CX3CR1-GFP+ microglia at 
a closer distance to the blood vessels. After MOG immu-
nization, the mice in the pre-symptomatic stage showed 
slightly more GFP signal in the parenchyma than the 
CFA animal (Fig. 2c). The parenchymal GFP signal fur-
ther increased, especially in proximity to the blood vessel, 
coinciding with morphological changes of the CX3CR1-
GFP+ cells towards a more amoeboid shape when the mice 
entered the symptomatic stages of EAE (Fig. 2d, e). During 
post-peak disease stage, still numerous amoeboid-shaped 
CX3CR1-GFP+ microglia were present (Fig. 2f). In EAE 
animals, also CX3CR1-GFP+ blood cells might have infil-
trated the spinal cord, adding to the numerous CX3CR1-
GFP+ amoeboid microglial cells, from which they cannot 
be distinguished, based on their morphology. Additionally, 
in the symptomatic stages of EAE (Fig. 2d–f), some red-
coloured CX3CR1-GFP+ cells in the parenchyma close to 
the blood vessels were observed (arrows). This was likely 
caused by cellular uptake of Rhodamine B isothiocyanate-
dextran leaked into the parenchyma. This was an EAE phe-
nomenon and not detected in the naïve animal or the CFA 
animal (Fig. 2a, b) or in asymptomatic animals (data not 
shown).
Cellular characterization of CX3CR1‑GFP+ cells
To confirm the monocyte/microglia identity of the 
CX3CR1-GFP+ cells in the spinal cord of our CX3CR1gfp/gfp 
mice induced with EAE, we immunohistochemically char-
acterized these cells in the spinal cord area that had previ-
ously been imaged by IVM and are hence from post-peak 
disease (n = 3, Fig. 3). Our observations revealed that 
CX3CR1-GFP+ cells in the white matter lesions expressed 
markers for microglial cells and macrophages, i.e. Iba1 
(Fig. 3a, b) and the phagocyte marker for lysosomal activ-
ity, CD68 (Fig. 3c, d). Furthermore, intense CD45 (Fig. 3e, 
f) immunoreactivity was found in the lesion areas, mainly 
in amoeboid-shaped cells (arrowheads and inserts). Moreo-
ver, co-localization of CD68 and CD45 in CX3CR1-GFP+ 
cells was found (Fig. 3g–i). We also observed ramified 
GFP+ cells that were weakly immunoreactive for CD45 
but not CD68, indicative of local microglia (arrows). This 
finding supports the hypothesis of influx of CX3CR1-
GFP+ from the vasculature into the spinal cord, although 
this was not observed during IVM. In a CFA animal, 
fewer and mostly ramified CX3CR1-GFP+ microglia were 
observed, uniformly distributed in the spinal cord (Supple-
ment Fig. 1). These cells were all positive for Iba1 (Supple-
ment Fig. 1a, b), but not for CD68 (Supplement Fig. 1c, d), 
indicative of a microglial phenotype. It has been described 
that CX3CR1-GFP+ cells can also comprise T and NK 
cells and therefore we stained for the presence of these cell 
types (Jung et al. 2000). CD3-positive T cells (Fig. 4a, b) 
appeared in the spinal cord lesions, although in low num-
bers compared to Iba1- and CD68-positive cells. Moreo-
ver, the CD3-positive T cells did not co-localize with GFP. 
NK cells were absent in the spinal cord lesions (Fig. 4c, 
d), although spleen tissue of the same animals showed 
NKp46+ cells that in small numbers co-localized with 
GFP+ cells (Fig. 4e, f).
IVM of GFP+ cells in the vasculature
Two-photon imaging revealed that CX3CR1-GFP+ cells 
in the vasculature of the naïve mouse rarely interacted 
with or crawled along the luminal side of the blood ves-
sel endothelium (~1 cell per 10 min) as depicted in Fig. 5a. 
We termed these cells fast moving cells. An animal injected 
with CFA and subsequently imaged at a time point post-
injection, comparable to the early disease phase in EAE 
animals, served as a control for the early stage of disease 
in EAE animals. The data showed a tendency of increased 
interaction of CX3CR1-GFP+ cells with the endothelium 
and around 15 cells per 10 min showed an extensive intra-
luminal crawling behaviour for longer than 25 s, which 
were designated crawling cells. A comparable amount of 
cells was observed in MOG-immunized animals during 
Fig. 1  EAE in CX3CR1gfp/gfp  
mice. a Clinical disease scores 
and b body weight after immu-
nization with MOG35-55  
(unfilled circle, n = 3) or 
CFA (filled circle, n = 1) in 
CX3CR1gfp/gfp mice with spinal 
cord window implants. Data 
represent mean–SEM
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Fig. 2  Representative two-photon IVM of CX3CR1-GFP+ cells in 
the spinal cord of CX3CR1gfp/gfp mice. CX3CR1-GFP+ cells in the 
parenchyma (arrowheads) resemble microglial cells. They display a 
ramified phenotype in a naïve (n = 1) and b the CFA animal (n = 1). 
In MOG-induced EAE (n = 3) animals (c–f), these cells morphologi-
cally change towards an amoeboid phenotype, with big cell clusters 
in symptomatic EAE (d–f). Furthermore, during EAE (c–f), the red 
Rhodamine B isothiocyanate-dextran (used to stain the blood ves-
sels) leaks into the parenchyma where it is then taken up by cells, 
resulting in red cellular staining (arrows). In addition to parenchymal 
locations, a–f CX3CR1-GFP+ cells were observed within the blood-
stream, specified by squares (colour figure online)
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Fig. 3  CX3CR1-GFP+ cells in 
EAE spinal cord tissue (n = 3) 
stained post-IVM are mono-
cytes/macrophages and micro-
glial cells. a, c, e, g Spinal cord 
EAE lesions in CX3CR1gfp/gfp 
mice show clusters of ramified 
and amoeboid CX3CR1-GFP+ 
cells with immunoreactivity 
for b Iba1, d CD68 and f CD45 
(arrowheads). Triple-positive 
cells for g GFP, h CD45 and i 
CD45 indicate that some GFP+ 
cells might have infiltrated from 
the bloodstream, while local 
ramified microglia (arrows) are 
GFP+ with low immunoreac-
tivity for CD45 and none for 
CD68. Insets provide higher 
magnification of double-/triple-
positive cells
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pre-symptomatic disease (Fig. 5a; pre). As EAE developed, 
the number of crawling cells was slightly reduced from 
pre-disease but remained elevated in all disease phases ana-
lysed, including post-peak disease. As another control, we 
imaged asymptomatic animals at a time point post-immuni-
zation that was comparable to post-peak disease. The num-
ber of crawling monocytes in asymptomatic mice was only 
half of the amount (~5 cells per 10 min) as found in post-
peak EAE, indicating that the elevated crawling of mono-
cytes is due to ongoing clinical EAE and not just due to the 
immunization as such.
A similar pattern of cell distribution was seen when 
the crawling cells were analysed as a percentage of total 
CX3CR1-GFP+ cells imaged within the circulation 
Fig. 4  Neither T cells nor NK cells are amongst the CX3CR1-GFP+ 
cells in the EAE spinal cord tissue stained post-IVM (n = 3). a, c 
CX3CR1-GFP+ cells in spinal cord EAE lesions in CX3CR1gfp/gfp 
mice do not display immunoreactivity for (b) CD3 (arrowheads, 
higher magnification in the inset) and (d) NKp46. e, f show GFP+ 
and NKp46 co-labelled cells in the spleen (arrowheads, higher mag-
nification in the inset), which served as a positive control for the 
NKp46 antibody
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(Fig. 5b). CFA immunization, as well as immunization 
with MOG, resulted in a significant increase in the percent-
age of CX3CR1-GFP+ crawling cells within the mouse 
spinal cord vasculature of naïve to the pre-symptomatic 
EAE phase. The percentage of crawling cells progressively 
reduced significantly during the disease course from more 
than 80% in pre-symptomatic disease to 46% in the post-
peak disease stage. In asymptomatic animals, only 15% of 
the cells were of a crawling phenotype, which was signifi-
cantly different from the CFA-injected control animal and 
the pre-symptomatic EAE animals.
Additionally, we examined the crawling movement of 
monocytes during their interactions with the endothelium. 
Plotting the individual crawling tracks revealed that the 
displacement and the direction of crawling changed over 
time of the EAE disease course (Fig. 6). In the naive ani-
mal, as already shown in Fig. 5, only few crawling mono-
cytes were present with a very limited local displacement 
(Fig. 6a). Consequently, they were excluded from fur-
ther analysis. CFA immunization led to a displacement 
of monocytes up to about 100 µm (Fig. 6b). In EAE-
induced animals (Fig. 6c–e), the displacement of crawling 
CX3CR1-GFP+ cells increased as disease progressed with 
a maximum at peak disease, displaying a displacement up 
to 200 µm. While the average track length presented lit-
tle differences between CFA and EAE animals (Fig. 6g), 
the distribution of the track length was altered within the 
different EAE phases (Fig. 6h). Of all CX3CR1-GFP+ 
crawling cells, 50–60% displayed track lengths of less 
than 100 µm. Intermediate track lengths of 100–200 µm 
were similar during the different stages of EAE, although 
there was a tendency that they were reduced compared to 
the CFA-induced tracks (Kruskal–Wallis test, p < 0.05, 
post hoc test not significant). Long distance displacement 
of crawling cells extending 200 µm distance was only 
observed in MOG-immunized animals with a significant 
increase to around 20% of total crawling CX3CR1-GFP+ 
cells during peak disease. Furthermore, as already shown 
in Fig. 6b–f, CX3CR1-GFP+ cells did not only crawl in the 
medial direction with the bloodstream, but also in the lat-
eral direction against the bloodstream (Fig. 6i). In CFA and 
pre-disease EAE animals, around 20% of CX3CR1-GFP+ 
crawling cells moved against the blood stream. With ongo-
ing EAE, this cellular behaviour reached around 35% of 
CX3CR1-GFP+ crawling cells in peak disease.
GFP+ cells in the spinal cord also express TG2
To study whether TG2 is present in our mouse EAE model, 
immunohistochemical analysis of spinal cord sections was 
performed. TG2 immunoreactivity was found in the blood 
vessels of all EAE animals (Fig. 7a, d, g, arrows) and of the 
naïve and CFA control animals (as exemplified for the CFA 
animal in Supplementary Fig. 2), as described before (van 
Strien et al. 2015). Additional cellular TG2 immunoreactiv-
ity was found in spinal cord lesions of EAE animals.
GFP+ cells, identified as Iba1 and CD68-positive micro-
glia and monocytes/macrophages, but not CD3-positive 
Fig. 5  Quantification of the amount and percentage of intralumi-
nal crawling CX3CR1-GFP+ monocytes during EAE. a The amount 
of crawling cells is expressed as the mean number of crawling cells 
counted per video in all available videos per disease stage or con-
trol and normalized to a time frame of 10 min +SEM; p = 0.0551, 
Kruskal–Wallis test. b The percentage of crawling cells of the total 
intraluminal CX3CR1-GFP+ cells increased significantly during the 
pre-clinical phase of EAE and remained elevated during on-going 
EAE compared to asymptomatic animals. The percentage of crawl-
ing cells per total number of intraluminal CX3CR1-GFP+ cells was 
calculated per video in all available videos per disease stage or con-
trol +SEM; *p < 0.05, **p < 0.01. The results presented include data 
from naïve (n = 1), CFA (n = 1), EAE (n = 2 per disease phase) and 
asymptomatic (n = 2) animals
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Fig. 6  Tracks of intraluminal crawling CX3CR1-GFP+ cells. Mono-
cyte crawling tracks are presented from a naïve (n = 1), b CFA 
(n = 1), and c–f EAE (n = 2) animals per disease phase. g Average 
track length of crawling cells. h Distribution of track lengths per ani-
mal group. i Percentage of crawling cells moving against the blood-
stream. Coordinates of each cell track were set to the same origin to 
determine medial (in direction of blood flow) or lateral crawling of 
CX3CR1-GFP+ cells. Cranial and caudal direction of cell crawling 
depended on the orientation of the imaged blood vessel. All data are 
expressed as mean values +SEM
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T cells in EAE lesions, showed TG2 immunoreactivity 
(Fig. 7a–i). Most TG2-expressing cells exhibited an amoe-
boid morphology which could be monocytes and mono-
cyte-derived macrophages. Furthermore, ramified micro-
glial cells in and near the lesion area were somewhat TG2 
positive. Intriguingly, we observed TG2 immunoreactivity 
in CX3CR1-GFP+ cells within the blood vessel attached to 
the lumen (Fig. 7j, k). No extensive amounts of these cells 
were found due to perfusion of the animals, but particular 
cells attached to the endothelium were existent. As TG2 
can contribute to immune cell apoptosis and is upregulated 
during this process (Sandor et al. 2016), we studied the 
presence of active caspase-3 in spinal cord EAE lesions. 
Only few cells immunopositive for the cleaved caspase-3 
fragments (17/19 kDa) were found and single cells were 
co-labelled with TG2, while others were not (Fig. 7l, m). 
Overall, the presence of active caspase-3-positive cells in 
the EAE-affected spinal cord was limited.
Discussion
The present study is one of the first to show the in vivo 
behaviour of circulating monocytes in the murine spi-
nal cord at various time points after EAE induction. We 
observed an increased crawling behaviour of monocytes 
in CX3CR1-GFP+ transgenic mice in EAE- and CFA-
immunized animals compared to a naïve control. This 
increase was most pronounced early after immunization 
and was observed in all animals that received adjuvants 
with or without MOG35–55. This indicates that this initial 
increase in monocyte crawling behaviour is rather due to 
general activation of the immune system, which is essen-
tial to induce EAE in MOG-immunized mice. Indeed, 
recent observations showed an increase in blood-derived 
monocytes already in the preclinical and early stage EAE 
(Barthelmes et al. 2016). We observed elevated intralu-
minal monocyte crawling during the early stages of EAE 
and, despite subsequent reduction to intermediate levels at 
later disease stages, the amount of crawling cells remained 
elevated in EAE mice compared to naïve and also asymp-
tomatic animals. Therefore, an ongoing immune response 
as found in symptomatic EAE mice, which is absent in 
asymptomatic animals, seems needed to keep the crawling 
behaviour of monocytes elevated. Moreover, the displace-
ment length of individual crawling CX3CR1-GFP+ mono-
cytes was most extensive during peak disease. Furthermore, 
TG2-positive CX3CR1-GFP+ cells could be identified in 
and near the blood vessels during EAE, indicating a role of 
TG2 in mouse EAE in these animals.
To perform in vivo IVM analysis of monocyte behav-
iour, the spinal cord was made accessible by a window 
implantation. Although such a surgery could slightly delay 
EAE onset as described previously for the C57BL/6 strain, 
it does not alter the overall progression or disease score 
in this transgenic mouse strain (Fenrich et al. 2013a). The 
CX3CR1gfp/gfp transgenic mice used in this study express 
GFP instead of the chemokine receptor CX3CR1 and are 
henceforth CX3CR1 knockout animals. While this receptor 
was shown to be involved in leukocyte adhesion and migra-
tion, the CX3CR1gfp/gfp transgenic mice still develop EAE 
(Huang et al. 2006). Of importance, experiments comparing 
CX3CR1gfp/gfp with heterozygous CX3CR1+/gfp revealed 
that only the migratory properties of NK cells are affected 
during EAE in CX3CR1gfp/gfp animals, leading to no NK 
cell recruitment to the EAE lesions (Huang et al. 2006). 
Although we cannot completely exclude changed monocyte 
crawling behaviour due to CX3CR1 depletion, the chemo-
taxis of monocytes and other leukocytes is not impaired as 
their recruitment to the site of inflammation is constant in 
homo-as well as heterozygous CX3CR1-GFP-expressing 
mice. We confirmed the impaired NK cell recruitment by 
the lack of NK cells in the spinal cord lesions, although NK 
cells expressing GFP were present in the spleen. For the 
first time, the described surgical approach of the spinal cord 
window implantation was used to access the spinal cord in 
the transgenic CX3CR1gfp/gfp mouse strain. Our observa-
tion of CD68-, CD45- and/or Iba1-positive CX3CR1-GFP+ 
cells in the EAE spinal cord lesions, as well as the clearly 
developed clinical symptoms, supports the notion that these 
mice can be used for IVM to analyse monocyte behaviour 
during EAE.
Using IVM analysis, we found that CX3CR1-GFP+ are 
still able to crawl along the endothelial lumen, despite their 
loss of the CX3CR1 receptor and supporting previous data 
(Huang et al. 2006). Although the number of experimental 
animals used in this study was very small, some interesting 
changes in the behaviour of CX3CR1-GFP+ cells in the spi-
nal cord vasculature were present between controls, EAE-
induced asymptomatic animals and EAE-diseased animals 
and also within the different disease phases of EAE. Only 
few of the CX3CR1-GFP+ cells were found in the spinal 
cord vasculature of a naïve animal which corresponds to 
previous observations (Auffray et al. 2007; Carlin et al. 
2013). When compared with the total number of intralumi-
nal CX3CR1-GFP+ cells, the data suggest that under con-
trol conditions, most monocytes are fast moving cells that 
do not interact with the endothelium. However, upon treat-
ment with CFA, more crawling monocytes were present 
at the luminal side of the blood vessel, likewise observed 
in the preclinical stage of EAE. This crawling monocyte 
behaviour remained present during the early stage of EAE 
and had a tendency to recede partially during continuing 
disease. Nevertheless, it seemed higher throughout disease 
compared with asymptomatic animals. Thus, activation of 
the immune system stimulates CX3CR1-GFP+ cells in the 
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mouse spinal cord vasculature to enhance their intralumi-
nal crawling behaviour, which remained present in EAE 
animals showing apparent disease symptoms. The obser-
vation that the percentage and number of monocytes inter-
acting with the endothelium had a tendency to decrease as 
clinical disease progressed might be unexpected, but may 
reflect the steady increase in monocyte migration into the 
CNS during disease progression, as shown by pathological 
studies (Kuerten et al. 2007; Recks et al. 2011). Of inter-
est is that a comparable disease-dependent behaviour has 
been shown for T cells in the same EAE model. This sug-
gests that T cells and monocytes behave in a related time-
dependent way during EAE (Kerfoot and Kubes 2002). 
Moreover, asymptomatic animals showed a low amount of 
crawling cells and also a low percentage of total CX3CR1-
GFP+ cells in the vasculature, at a time point post-immu-
nization comparable to post-peak disease. This is in line 
with the idea that the disease-induced change in mono-
cyte intraluminal crawling behaviour contributes to or is a 
consequence of ongoing clinical EAE and not due to the 
immunization itself.
Subsequent analysis of the tracks of crawling mono-
cytes showed that the average track length did not differ 
between the control and EAE animals, but there is a clear 
change in maximum displacement of the crawling cells as 
well as crawling direction over the disease course. In par-
ticular, during peak disease, numerous monocytes showed 
extended crawling displacement along the endothelium, 
not only in the direction of the blood flow but also against 
it. Both of these observations could be a consequence of 
firmer interaction with the endothelium mediated by solu-
ble factors, e.g. chemokines and cytokines, secreted by 
local cells to actively attract more cells to the CNS (Red-
ford et al. 1997; Leppert et al. 2001; Goldmann and Prinz 
2013). Additionally, upregulation and activation of adhe-
sion molecules on endothelial cells could be responsible for 
the extended crawling of monocytes in the lumen (Rossi 
et al. 2011).
Along with CX3CR1-GFP+ monocytes in the circula-
tion, we observed CX3CR1-GFP+ cells in the spinal cord 
parenchyma. Under normal conditions, they reflect rami-
fied microglial cells, but upon inflammatory conditions 
such as EAE, a clear increase in the amount of CX3CR1-
GFP+ cells around the blood vessels becomes evident. It is, 
however, not possible to distinguish infiltrating monocytes 
from amoeboid microglia based on their GFP expression. 
Nonetheless, extensive immunoreactivity of the blood leu-
kocyte marker CD45 on CX3CR1-GFP+ amoeboid-shaped 
cells in the spinal cord parenchyma indicates that indeed 
cellular infiltration of blood-derived CX3CR1-GFP+ cells 
had occurred. The density of ramified microglia around 
the blood vessels was increased since microglia migrate 
towards lesion sites, where the activated microglia can 
proliferate and enable phagocytising properties such as 
taking up myelin and cell debris (Yin et al. 2010; Ajami 
et al. 2011; Chastain et al. 2011). The phagocytic capacity 
of CX3CR1-GFP+ cells is illustrated in the present study 
by Rhodamine B isothiocyanate-dextran uptake that had 
leaked from the circulation in EAE animals, but was neg-
ligible in control animals (naïve, CFA). The presence of 
the dextran in cells in the later stages of EAE can be either 
due to continuous uptake because of continuously damaged 
BBB integrity or slow intracellular degradation while the 
BBB had already been repaired.
Finally, we observed the multifunctional enzyme TG2 
in GFP+ microglial cells and monocytes/macrophages in 
the spinal cord lesions. Since TG2 immunoreactivity is 
only observed in or near lesion areas and not in ramified 
microglia in non-affected spinal cord, it seems that TG2 is 
associated with inflammatory infiltrates and/or microglial 
activation in mouse EAE. Interestingly, also GFP+ mono-
cytes attached to the luminal side of the blood vessel were 
found to exhibit TG2 immunoreactivity. However, due to 
transcardial perfusion, these cells were scarce. Since TG2 
is, amongst other functions, known to be involved in mono-
cyte adhesion and migration in vitro (Akimov and Belkin 
2001), we hypothesize that it might also be involved in the 
adhesion and migration processes in vivo. The presence of 
TG2 not only in the lesions but also at the luminal side of 
blood vessels supports previous findings on the involve-
ment of TG2 in monocytes in EAE.
Furthermore, TG2 is known to contribute to apop-
totic processes (Tatsukawa et al. 2016). During EAE, we 
observed very few cells in spinal cord lesions to express the 
apoptotic marker active caspase-3. This is in accordance 
with previous observations in mouse EAE (Irony-Tur-Sinai 
et al. 2009). Of the active caspase-3-immunopositive cells, 
single cells co-labelled with TG2 while others did not. 
Thus, little apoptotic processes are ongoing in EAE, and 
there is probably a minor role for TG2 in these processes.
Taken together, the observations in the present study 
showed that MOG immunization increased luminal mono-
cyte crawling behaviour, which remained elevated during 
EAE. Moreover, our results revealed that circulating mono-
cytes in EAE animals produced TG2, which may contribute 
Fig. 7  TG2 immunoreactivity in postmortem spinal cord of 
CX3CR1gfp/gfp EAE mice (n = 3). a, d, g TG2 immunoreactivity is 
present in blood vessels (arrows) and cells (arrowheads) in spinal 
cord lesions of mice suffering from EAE. In these lesions b Iba1, e 
CD68 and h CD3 immunoreactivity is observed. TG2 is co-local-
ized with c Iba1 and d CD68 and thus microglia and monocytes/
macrophages, but not i CD3-positive T cells. j, k GFP+ and TG2 
co-labelled monocytes can be found within the blood vessel (arrow-
heads). Blood vessels are presented in a sagittal (j) and coronal (k) 
direction. l, m Few cells in the EAE spinal cord lesions express 
cleaved caspase-3, which can co-label with TG2 (arrowhead). 
Squares represent cells shown at higher magnifications in the insets
◂
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to monocyte crawling and adhesion. We put forward that 
selective interference with monocyte crawling and migra-
tion behaviour should be applied in a very early stage of 
disease with the aim of counteracting disease progression. 
By means of the conducted experimental setup, future 
experiments on the effect of TG2 inhibition on monocyte 
behaviour can be assessed in vivo which may lead to novel 
treatment options for MS patients.
Materials and methods
Animals
Adult homozygous CX3CR1gfp/gfp mice, 7 weeks of age and 
older, were used in this study (Jung et al. 2000). All animal 
experiments and surgical procedures were approved by the 
National Animal Studies Committee of France (authoriza-
tion no. 13,300), as well as approved and authorized by the 
National Committee for Ethic in Animal Experimentation 
(Section No. 14; project 86-04122012). The experimental 
setup of the presented study is depicted in Fig. 8a.
Spinal cord surgery and window implantation
Microsurgical implantation of the spinal cord window was 
performed as described previously (Fenrich et al. 2012, 
2013a). Briefly, the mouse spinal cord was exposed from 
the thoracic vertebra 13 (T13) to lumbar vertebra 1 (L1), 
and a piece of glass was fixed over the exposed spinal cord 
to provide permanent optical access to the exposed spi-
nal cord (Fig. 8b). A few hours past the window implan-
tation, the animals were highly mobile and showed little 
or no signs of pain. Importantly, animals with implants 
groomed and behaved normally, did not show any signs 
of motor dysfunction, and continued to gain weight. After 
window implantation, a layer of vascular tissue can develop 
between the window and CNS tissue (Fenrich et al. 2012, 
2013a, b). To limit the thickness and optical density of this 
vascular tissue and to provide post-operative analgesia and 
anti-inflammatory treatment, dexamethasone (0.2 mg/kg) 
and Rimadyl (5 mg/kg) were injected subcutaneously every 
other day for 10 days.
Induction of EAE
EAE was induced 3–4 weeks after window implantation 
(i.e. 2–3 weeks after cessation of analgesic and anti-inflam-
matory treatment) when the window was clear and no 
fibrosis or signs of inflammation were visible. The entire 
experimental scheme is shown in Fig. 8a. Mice were lightly 
anaesthetized with isoflurane (Baxter, 1.75% in air (v/v) for 
1–2 min) to protect the spinal cord window from any strain 
due to mouse handling during EAE induction. Mice were 
injected subcutaneously in each flank and the base of the 
tail with a total of 75 µg myelin oligodendrocyte protein 
peptide (MOG35–55, Tocris) in complete Freund’s adjuvant 
(CFA), containing 800 µg Mycobacterium tuberculosis (BD 
Biosciences). In addition, mice received 400 ng pertussis 
toxin in PBS (Sigma Aldrich) intraperitoneally on the day 
Fig. 8  Setup of experimental procedure. a Spinal cord window 
implantation is followed by anti-inflammatory treatment and a 2- to 
3-week clearance period before EAE induction and IVM; b IVM 
imaged area of the spinal cord included the venules draining into the 
central dorsal vein around the vertebrae level T13–L1
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of immunization and 2 days later. Animals were weighed 
and clinical symptoms assessed daily, as described before 
(Nikic et al. 2011): 0: no detectable clinical signs, 0.5: par-
tial tail weakness, 1: tail paralysis, 1.5: gait instability and/
or impaired righting ability, 2: hind limb paresis, 2.5: hind 
limb paresis with partial dragging, 3: hind limb paralysis, 
3.5: hind limb paralysis and forelimb paresis, 4: hind limb 
and forelimb paralysis, 5: moribund.
Two‑photon intravital imaging
For each imaging session, mice were anaesthetized with 
1.75% isoflurane for 2 min, followed by intraperitoneal 
injection of ketamine (100 mg/kg) and xylazine (10 mg/
kg). For sessions exceeding 1 h, light anaesthesia was 
maintained with 0.2–0.75% isoflurane starting from about 
45 min after beginning of the imaging session until com-
pletion. To acquire a visual contrast of blood vessels dur-
ing imaging, mice were injected with either 2 μg of QDot-
655 (Qtracker 655, non-targeted quantum dots; Invitrogen) 
or 2.4 mg Rhodamine B isothiocyanate-dextran 70 kDa 
(Sigma) in PBS, immediately before data acquisition via 
tail vein or retrobulbar injection. A tuneable femtosec-
ond pulsed laser (Mai-Tai, Spectra-Physics) was used at 
900 nm wavelength and coupled to an upright two-photon 
microscope (Zeiss, LSM 7MP) with a 20× water immer-
sion objective lens (NA = 1.0) and five non-descanned 
detectors. The spinal cord window and imaged area are 
shown in Fig. 8b. The imaged vessels included the left 
and right venules draining into the central dorsal vein of 
the murine spinal cord. An area of 212.55 × 212.55 μm 
with a resolution of 0.41 μm per pixel and 5 μm distance 
between the individual planes of the stacks was scanned. 
30–50 µm deep stacks were acquired with an acquisition 
rate of one plane per second. The imaging duration of the 
individual videos varied from 7:23 to 19:05 min and con-
tained 35–80 stacks.
Analysis of CX3CR1‑GFP+ cells in the circulation
Videos and images were analysed with the ZEN lite soft-
ware (Zeiss) and Fiji with the MTrackJ plug-in (Meijer-
ing et al. 2012; Schindelin et al. 2012). IVM analysis was 
performed on raw data, but IVM figures shown here were 
pseudo-coloured as well as contrast enhanced.
To analyse the behaviour of GFP+ cells in the blood ves-
sels of the spinal cord, the cells were separated into two 
groups: (1) fast moving cells, which shortly interact with the 
endothelium, and (2) crawling cells that interact extensively 
(>25 s) with the endothelium. The presented data reflect 
the quantification of cells of several blood vessels from 
one naïve animal, one CFA animal and two EAE animals 
per disease stage: (1) preclinical EAE when no symptoms 
are apparent yet, (2) early disease, (3) peak disease and (4) 
post-peak disease (Fig. 8a). In addition, two mice that were 
asymptomatic despite MOG immunization were analysed. 
Per disease stage, a total of 80–340 cells present in five to 
ten videos were examined. Besides the number of CX3CR1-
GFP+ cells, their intraluminal crawling movement along the 
endothelium was tracked and normalized to the same origin 
as well as medial and lateral crawling direction. All graphs 
were generated using GraphPad Prism 6 and microscopical 
image panels were created using Adobe Photoshop CS6.
Tissue processing and immunohistochemistry
At the end of the IVM experiments, i.e. day 25–33 after 
EAE immunization (equivalent to post-peak disease), the 
mice were transcardially perfused with saline followed by 
20–30 ml of 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4). Spinal cords and spleen were dissected 
and post-fixed for 2 h at 4 °C. Tissue was cryo-protected 
with 10% sucrose in PBS and embedded in OCT tissue tek 
(VWR Chemicals). Coronal sections (10 μm) were cut, 
dehydrated and stored at −80 °C until immunostaining.
Table 1  Primary antibodies for immunohistochemistry
Target Origin Dilution Supplier Code
Iba1 Rabbit 1/1000 Wako chemicals 019-19741
CD68 Rat 1/300 Serotec MCA1957
CD68 Rabbit 1/400 Abcam ab125212
CD45 Rat 1/10 Gift from dept. Molecular Cell Biology and 
Immunology, VUmc, Amsterdam
clone MP33
CD3 Rat 1/100 AbD Serotec MCA500G
NKp46-biotin Goat 1/100 R&D Systems BAF2225
TG2 Mouse 1/100 Prof T. J. Johnson
Sheffield University, UK (gift)
Clone IA-12
Cleaved caspase-3 (Asp175); 17/19 kDa fragments Rabbit 1/350 Cell Signaling Technology #9661
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For single immunohistochemical stainings, sections 
were thawed, blocked in 3% BSA in TBS containing 0.5% 
Triton X-100 (TBS-T; Sigma), and incubated with primary 
antibodies for Iba1, CD68 (rat), CD3 or CD45 (Table 1). 
For double staining of CD45 and CD68 (rabbit), incubation 
of both primary antibodies was done at once. All sections 
were incubated with primary antibodies at 4 °C overnight 
followed by three 5 min washes in PBS. The sections were 
then incubated with appropriate AF594 or AF633-labelled 
IgGs (1/400, Molecular probes) in TBS-T for 2 h at room 
temperature.
Before staining of NKp46 (Table 1), endogenous per-
oxidases were quenched (0.3% H2O2, 0.1% sodium azide 
in TBS) and sections incubated with primary antibody for 
1.5 h at room temperature. After washing, ImmPRESS 
HRP anti-goat IgG polymer detection kit (Vector laborato-
ries) was added for 30 min before slides were washed and 
incubated for 10 min with the TSA™ reagent Alexa Fluor 
594® tyramide (1/100 in amplification buffer, Thermo 
Fisher Scientific).
Immunohistochemical co-labelling of TG2 and the 
above used immune cell markers (Table 1) required pre-
treatment with a mouse on a mouse blocking kit (M.O.M.; 
Vector Laboratories) according to the manufacturer’s 
guidelines. Briefly, the sections were blocked for 1 h 
with blocking reagent and the staining was continued as 
described above with additional AF633-labelled donkey 
anti-mouse IgG’s (1/400, Molecular probes) to detect 
TG2.
For double-labelling of TG2 and cleaved caspase-3 frag-
ments (17/19 kDa) (Table 1), endogenous peroxidases were 
blocked, M.O.M blocking was applied and sections were 
incubated with antibodies as described above. ImmPRESS 
AP anti-rabbit IgG polymer detection kit (Vector laborato-
ries) was added for 30 min, slides were washed and EnVi-
sion+ kit HRP anti-mouse (Dako) was applied for 30 min. 
After washing, the slides were first incubated with liquid 
permanent red (LPR, Dako) as AP substrate and then after 
a quick wash with DAB+ (Dako) as HRP substrate, both 
according to manufacturer guidelines.
All slides were coverslipped with polyvinyl alco-
hol mounting medium with DABCO (Fluka) and all 
fluorescent slides were examined with a confocal laser-
scanning microscope or a fluorescence microscope 
(Leica TSC-SP2-AOBS and Leica DM5000B, Leica 
Microsystems). The light-microscopical double staining 
for cleaved caspase-3 fragments (17/19 kDa) and TG2 
was analysed with a Nuance spectral imaging camera 
(Nuance) and displayed in colours representing fluores-
cent staining to increase the visual contrast. As negative 
staining control, primary antibodies were omitted, which 
resulted in minor or no background immunoreactivity 
(data not shown).
Statistical analysis
IVM data were not normally distributed and therefore sta-
tistically analysed using the non-parametric Kruskal–Wal-
lis test followed by Dunn’s multiple comparison test using 
GraphPad Prism 6. Differences were considered significant 
if p < 0.05, and considered a trend if p < 0.06.
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